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Tumor necrosis factor a (TNF) is a potent activator of
transcription directed by the human immunodeficiency
virus type 1 (HIV-l) long terminal repeat (LTR). We have
recently reported that the p53 tumor suppressor gene
product binds to a site within the Spl binding region of
the HIV-l LTR and contributes to the TNF induction of
this promoter. In this study we show that the transcrip-
tion factor SpI cooperates with p53 in the transcrip-
tional activation directed by the HIV-l LTR. The pres-
ence of SpI increased p53 binding to its recognition
sequence in the HIV-I LTR, and experiments in Drosoph-
ila cells show that Spl is necessary for full transactiva-
tion by mutant p53. Importantly, TNF induced the asso-
ciation between p53 and Spl in Jurkat T cells. These
data demonstrate a synergistic role for these proteins in
the mechanism ofTNF induction ofHIV-l LTR-mediated
transcription and suggest that SpI may play an impor-
tant role in modulating certain functions of p53.
Transcriptional activation of HIV_11 gene expression is con-
trolled in part by the interaction of sequence-specific transcrip-
tion factors with the long terminal repeat (LTR) region (1, 2).
Two of these factors, NF-KB and BpI, have been studied inten-
sively. NF-KB is an inducible transcription that binds two de-
scribed DNA elements in the HIV-l LTR. BpI is an approxi-
mate 100-kDa protein that is ubiquitously expressed in
mammalian cells, and three BpI sites have been described in
the LTR that are downstream of the NF-KB sites (1-3). Al-
though a number of cytokines have been shown to modulate the
expression of the human immunodeficiency virus 1 (HIV-l),
only TNF is known so far to activate viral replication in both T
cells and mononuclear phagocytes (4). This cytokine is a potent
activator of transcription factors that have been shown to reg-
ulate HIV-l LTR-mediated expression (5, 6).
The p53 tumor suppressor gene product is a sequence-spe-
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cific DNA-binding protein, which acts as a transcriptional acti-
vator or repressor of a number of genes (7-15). The frequent
appearance of tumors in the p53 null mice suggests that p53
functions as a tumor suppressor agent (16). However, experi-
ments with antisense p53 (17), microinjection of anti-p53 anti-
bodies (18), and transcriptional assays utilizing transforming
mutant p53 forms (6,13, 14, 19) indicate that p53 presents addi-
tional functions that are independent of growth suppression. It
has been demonstrated recently that overexpression of mutant
p53 in cells that completely lack endogenous p53 led to a dra-
matic increase in HIV-l replication in vivo (20). In addition, it
has been shown that mutant and wild type p53 transactivate and
repress, respectively, HIV-l LTR-directed transcriptional activ-
ity (6,19) and that the p53, BpI, and TATA box sites are involved
in the p53-induced effects on this promoter (6, 19, 20). Addition-
ally, we identified an inducible form of p53 in Jurkat T cells that
directly interacts with a sequence element positioned immedi-
ately 3' to the most 5' BpI binding site (6).
Here we report that TNF induces a physical interaction
between p53 and BpI and that this interaction is important for
p53 DNA sequence recognition and transactivation of the
HIV-l LTR. These data indicate a significant functional role for
the interaction of both proteins in the mechanism of TNF
induction of HIV-l transcription and suggest a role for BpI in
modulating specific biological functions of p53.
EXPERIMENTAL PROCEDURES
Electrophoretic Mobility Shift Assays-The LTRA and B sequenceswere
as indicated in Fig. 1 (duplexes). Other oligonucleotides used were (duplex-
es): p53m ( CAGGGAGGCGTAAACTGGGCGGGACTGGGG) and Splm
(CAGGGAGGCGTGGCCTGGG'ITITACTGGGG). DNA oligonucleotides
and gel shift mobilityassays were prepared as describedpreviously(6),but
0.5p.g/p.l bovineserum albumin was added when recombinantproteins were
assayed. PurifiedSpl fromHeLacellswas fromPromega.Purifiedwildtype
p53 was a gift from P. Tegtmeyer. Purified proteins GST-YB-l, GST-Z
(BZLFl), E2F, CEBP/3, and Egr-l were a gift from G. MacDonaldand J.
Ting,S. Kenney,N.Sung, S.McKnight,and V.Sukhatme, respectively. YYl
was expressed and purified as described(21).
[]V Cross-linking-Several templates for UV cross-linking were pre-
pared. LTR A-UVis an LTR A probe with a BrdUrd for T substitution
at position 25. LTR B-UV is a LTR B probe with BrdUrd for T substi-
tutions at positions 11 and 24. IO-fold scale-up EMSA reactions were
prepared and irradiated for 20 min at room temperature with 312 nm
UV light. Reactions were loaded onto 3.8% polyacrylamide gels and run
as indicated. DNA-protein complexes were identified by autoradiogra-
phy, excised, and loaded on a 10% SDS-PAGE gel (Bio-Rad).
Biotin-Oligonucleotide Affinity Precipitation ofp53-100 p.gof nuclear
extracts from TNF-induced Jurkat cells were incubated with 100 ng of
biotinylated probes and 100 p.gof poly(dI-dC)'(dl-dC) for 20 min at room
temperature. Streptavidin Magnesphere beads (150 p.l, Promega) were
added and the mix incubated for an additional 15 min, followed by pre-
cipitation through a magnetic field. The pellet was resuspended in 250 p.l
of phosphate-buffered saline with 10 p.gof poly(dI-dC)'(dI-dC), reprecipi-
tated, and the presence ofp53 determined by Western analysis.
Antibodies, Immunoprecipitations, and Western Blotting-Mouse
monoclonal anti-p53 PAb 240, PAb 421, and PAb 1801 and rabbit
polyclonal anti-Spl antibodies were purchased from Santa Cruz. Mouse
monoclonal anti-p53 1620 and anti-MDM2 were from Oncogene Sci-
ences. Immunoprecipitations and Western blotting were carried out as
recommended by the suppliers. EMSA-Western blotting experiments
were performed essentially as described (22). EMSA reactions were
carried out with probe LTR B and the position of the TIC3 band
identified by autoradiography. Gel slices containing this band were
isolated, and proteins were transferred to Immobilon-P membranes
(Millipore). The membranes were probed with anti-Spl antibody (1:
2000) and anti-p53 antibody PAb 1801 (1:500).
Plasmids-HIV-l LTR CAT reporter plasmid constructs were a gift
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sequence is blocked by incubation of th e extracts with anti -
bodies that recognize p53 in a prolifera tive (mutant-like) con-
form ation (6). Anoth er two inducible complexes of slower mo-
bility (TIC3 and TIC4) were detected usin g LTR B (Fig. lA ).
Th e slower mobili ty of TIC3 suggested th at, aside from p53,
an additiona l factor was presen t in this complex. To determine
whether p53 and Sp1 were part of TIC3 and TIC4, th e sa me
extracts were incubated with antibodies that recognize eithe r
Sp1 or p53 epitopes and th en ana lyzed by EMSA with the LTR
B probe (Fig. 1B). Th e a nti-Sp l antibody supershifted the up-
per TIC complex (TIC3) ind icating th e presence of this t ra n-
scription factor . Three ant i-p53 monoclon al antibodies were
used : PAb 421 , PAb 1620, and PAb 1801. PAb 421 is a mono-
clonal antibody against wild type and mutant p53 C-te rminal
domain. PAb 1620 is specific for a nonproliferative conform a-
tional epitope of wild type p53. PAb 1801 recogniz es wild type
an d mutant p53 N-terminal domain. Only PAb 421 was ab le to
detect p53 in the EMSA. Addition of this antibody complet ely
blocked TIC formation (Fig. 1B). The effect ofPAb 421 was not
proteolytic since this antibody was ab le to supershift p53 bound
to the consensus RGC p53 site (not shown). Interestingly, th e
p53 PAb 421 epitope ha s been shown to be expressed when
lymphocytes are induced to proliferate by mitogens (25), and
expression of this epitope in th e abse nce ofPAb 1620 reactivity
is considered to identify a p53 conform ational state associated
with cell proliferation (26). In order to provid e further evidence
for the pre sence of Sp1 and p53 in th e TICs, we transferred th e
major inducibl e complex , TIC3, from th e EMSA to a membran e
and probed with antibodies specific for Sp1 or for p53. Rabbi t
anti-Sp l and PAb 1801 identified th e presence of both protein s
in TIC3 (Fig. Ie). In conclusion, th e EMSA-supershift and
EMSA-Western experiments indica ted that p53 is present in
both TIC3 and TIC4 and th at p53 and Sp1 constitute th e TIC3.
The specificity of the TICs was demonstrated by EMSA oli-
gonucleotide competition experiments. Nucle ar extra cts from
TNF-induced J urkat cells were preincubated with a 500-fold
molar excess of oligonucleoti des containing native LTR B se-
quences or LTR B seq uences with mutations in th e p53 (LTR B
p53m) or Sp1 (LTR B SpIrn ) sites, or with the p53 consensus
RGC sequence. EMSA ana lysis is shown in Fig. 1D. The TIC
bands were complete ly competed by the LTR Band LTR B
Sp1m seq ue nces , indicating that th e p53 site is necessary for
the TIC complexes to bind . Competition with LTR B p53m only
part ially competed TIC formation and the RGC oligonuc leotid e
had no effect . As demonstrated previously (6), TNF-inducible
p53 does not bind the RGC consensus p53 site (Fig. ill).
In order to determine if the presence of th e Sp1 bin ding site
substant ia lly modified th e affinity of p53 for th e HIV-1 LTR,
experiments were designed to test th e ability of biotinylated
oligonucleotides containing LTR B native or mutant sequences
to affinity precipitate p53 from nucl ear extra cts. TNF- induced
Jurkat nuclear extracts were incubated with oligonucleotid es
biot in-LTR B, biotin-LTR B p53 mutant , or biotin-LTR B Sp1
mutant. Protein-DNA complexes were precipitated with
streptavidin magnetic beads and were analyzed by immuno-
blotting. A typical result of th ese experiments, shown in Fig.
IE, indicated that Sp1 binding to th e DNA probe enhanced th e
affinity ofp53 for its LTR binding site . Mutation of the p53 site
completely blocked p53 binding (Fig. IE , lane 2). Although
mutation of th e Sp1 site did not block p53 bin ding, it affected
p53 binding in a significant manner, ranging from 50% to 25%
of p53 bound to the Sp1 mutant probe relative to th e native
probe (Fig. IE, lane 3). These data suggested that an interac-
t ion between Sp1 and p53 alters the binding affinity of p53 for
its target on the HIV-1 LTR or that Sp 1 bindi ng to its site
enhances p53 binding through alteration of DNA conformation .
- TIC 3
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We have shown pr eviously th at a binding site interacting
with a TNF-inducible form of p53 is present in the HIV-1 LTR
(Fig. 1) (6). Thi s binding site is situate d between the most 5'
(Sp1 III ) and the middle (Sp1 II ) HIV-1 LTR Sp1 sites (3, 6).
The pr esence of th e p53 site overlapping th e 5 ' flank of th e Sp1
II site prompted as to study a possible interaction between both
transcription factors on th e HIV-1 LTR sequences. For this
purpose, two oligonucleotides, LTR A and LTR B, were synthe-
sized. Oligonucleotide A contains th e most 5 ' Sp1 site (site III )
along with th e recently reported p53 binding site. Oligonucleo-
tide probe LTR B (Fig. 1) contains th e p53 site an d the complete
Sp1 site II . Jurkat T cells were incubated for 1 h in the presence
or absence of 10 ng/ml TNF, after which nuclear extracts were
pre pared and assayed by EMSA using the LTR A and B probes.
Two TNF-inducible complexes (TIC1 an d TIC2) were detected
with the LTR A pr obe (Fig. lA ). It has been previously re ported
that these complexes contain p53 and that p53 binding to this
o Competitor:
None LTRB p53 Spl RGC
rnut mut
E
LTR B p53 Spl
rnut rnut
from B. Stei n. Th e cytomega lovirus (CMV) enha ncer -promote rdriven
expression vectors cont aining wild type p53 and the tumor-promoting
p53ala form were a gift from B. Vogelst ein . Spl mammalian expression
vectors wer e as described in Ref. 23. The pPAC and pPAC-Spl expres -
sion plasm ids were kindly provided by R. Tjian .
Cell Culture, Cell Extra cts, Tran sfections, and CAT Assays---Jurkat
T leuk emia and Akata cells from ATCC were cultured and transfected
as describe d (6). Nuclear cell extra cts were prepared as described (24),
but a fina l concentration of 2 rnxt phenylmethylsulfonyl fluoride was
used. Extracts were aliq uoted and stored at - 80 °C. Drosophila mela-
nogaster SL2 cells were cultured in Schn eider 's media (LCCC Tissue
Culture Facil ity ) and supplemented with 10% fetal bovine serum. Cells
were tr an sfected by electropora tion (300 V, 960 microfar ads ) a t 5 X 106
cells/O.5 ml of phosphate-buffered sa line and resuspend ed in 10 ml of
media . Incubations were carried out for 48 h (J urk at and Akata cells) or
72 h (SL2 cells ). CAT activi ty was assayed as described in Ref. 6.
FIG. 1. A, EMSA showing a compari son of the TNF-induced complexes
with the LTR A and LTR B probes. Jurkat cells were incubated in the
abse nce (- TNFJ or presence (+ TNFJ of rTNF-a, processed for the prep-
aratio n of nuclear extracts assayed by EMSA. B, EMSA-antibody blocking
experiment cha racterizing TNF- indu ced protein-LTR B complexes. C,
EMSA-Weste rn blottin g identifying the presence of Spl and p53 in TIC3
using an LTR B probe. D, EMSA competi tion experiment with TNF-
induced extracts and th e LTR B probe. 500-fold excess of the oligonucleo-
tide compet itors were used as indicate d in the figure. E, Western blot of
biotin-LTR B affinity-purified p53 form TNF-induced Jurkat nuclear ex-
tracts. Biotin-LTR B (53m) and biotin-LTR B (Splrn) are biotinylated LTR
B oligonucleotides with muta tions in th e p53 and Spl sites, respectively.
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FIG. 2. A , effect of TNF on th e coimmunoprecipitation ofp53 with Sp l
in J urka t cells. Cell lysates were prepar ed and Spl imm un oprecipi-
tat ed . Immunoprecipita tes were assay ed by Western blotting for the
presence of p53. B, effect of TNF on th e coimmunoprecipitati on of Sp l
and MDM2 with p53 in Jurkat cells. Cells were assayed as in A and p53
immunoprecipitated wit h PAb 240. Th e presence of Spl and MDM2 was
detected Western blotting.
TNF Indu ces the Association of p53 and Sp l in J urkat
Cells- To determine if p53 an d Sp1 associate in J urkat cells
following TNF induction , we perform ed coimmuno precipitation
studies. Sp1 and associated proteins presen t in the cell extracts
were immunoprecipitated with ant i-Sp1 and analyzed by
PAGE. The pr oteins were transferred to a membran e and the
poten tial presence of p53 was measured by probing with anti-
body PAb 180 1. The results shown in Fig. 2A demonstrate that
TNF induced the as sociation of p53 and Spl . In the experiment
shown in Fig. 2A, the amount of p53 bound to Sp1 in uninduced
cells was practicall y undetectable. In simila r experiments,
some p53 was coimmunoprecipitated with Sp1 in un trea ted
cells but always the amount of p53 in un induced cells was
signific antly less that the amount coimm unoprecipitated with
Sp1 in TNF-induced cells . The overall levels of p53, as deter -
mined by Western ana lysis, did not change du ring the incuba-
tion with TNF (not shown ). In terestingly, it has been shown
pr eviously that Sp1 and p53 are able to intera ct in an erythro-
leukemi a cell line induced with granulocyte/ma crophage
colony-stimulat ing factor (27).
In reciprocal experiments, cells were TNF induced , lysed and
p53 was precipitated with PAb 240. Extracts were an alyzed by
PAGE and probed with anti-Sp1 antibody (Fig. 2B). Th e
amount of Sp l interacting with p53 was increased by the treat-
men t of th e cells with TNF. Sp1 was also coimmunopre cipi-
tated with p53 when anti-p53 PAb 421 was us ed (not shown).
As a control, th e membran e was probed for th e presence of
MDM2, a protein that has been shown to intera ct with p53 (28).
In triguingly, a decrease in the am oun t of MDM2 in teract ing
with p53 was found in the TNF induced cells. It is kn own that
human MDM2 inhibits the ability of p53 to stimula te transc rip-
tion by binding to the acidic act ivation domain of p53 (28, 29).
We specula te that MDM2 may also be inhibit ing p53 tran scrip-
t iona l activity by blocking the ability of p53 to interact with
other transcription fact ors. Thi s would also suggest that the
regulation of MDM2-p53 interaction could be involved in the
mechanism of TNF fun ction. It has been previously shown that
the p53 PAb 240 epitope is induced by the incubat ion of lym-
phocytes withTNl" (6). Th e presen t da ta suggest that post-
trans lational modifications induced by TNF allow p53 to inter-
act with othe r transcri ptio na l activators , such as Spl. As
previously state d, it has been shown (27) that granulocyte/
macrophage colony-sti mulating factor induced the interaction
of p53 with Sp1 in erythro leukemia cells. It is presumabl e that
th e cytokine-induced modifications to p53 an d the subsequent
interaction with Sp1 play an importan t role in the ability of p53
to bind and transactivate certain of its DNA targets.
Spl Int eraction Is Necessary for Wild Type p53 to Bind the
HN LTR p53 S ite in Vitro- In order to further analyze the
FIG. 3. A , EMSA of p53 and Sp l usin g the LTR A probe. 100 ng of
purified Sp l and p53 were ut ilized. Gel shift assay conditions were as
indicat ed under "Experimenta l Procedures." B, EMSA of p53 and Spl
usin g the RGC and LTR B probes. Conditions were as in A. C, cross-
link ing of purifi ed Sp l and p53 protein s to LTR A-UV (LTR A ) and LTR
B-UV (L TR B) probes.
_ -Spl
III - p53
interaction between Sp1 and p53, we assayed the ability of
pu rified proteins to bin d different probes in vitro. As expected,
baculovirus-expressed wild type p53, bu t not purifi ed Sp1 from
HeLa cells , was able to bind the RGC probe (Fig. 3B ). As
indicated previously, our conditions of assay do not favor Sp 1
binding. Sp1-LTR A complexes were identified when the reac-
tion conditions were modified (lower stringency) for that pur-
pose (not shown). p53 and Sp1 were not able to independently
bind the LTR A probe (Fig. 3A). As shown in Fig. 1, the LTR A
probe does not contain the high affinity GGGCGG conse nsus
Sp1 binding site. Addit ion of Sp1 dr am ati cally increased p53
binding to this probe. The fact tha t p53 is the protein that bind s
the LTR A site in these gels was demonstrated by a cross -
linking experiment using an LTR A probe with a BrdUrd sub-
stitution at posit ion 25 (probe LTR A-UV). Sp1 and p53 were
incuba te d with LTR A-UV for 1 h an d irradiated for 15 min
with 312 nm UV ligh t , and complex form ation was determined
by EMSA. The unique band present in the EMSA was excised
and ana lyzed by PAGE (Fig. 3C, LTR A ), and only p53 was
detected . Thi s resul t shows that p53 is able to bind the LTR A
probe, and, although p53 and Sp 1 may be able to inte ra ct in
solution, the strength of this interact ion may not be sufficient
to res ist the conditions of the EMSA. Several experiments were
done to demonstrate the specificity of the activat ion effect of
Sp1 on p53 binding. First, Sp1 did not increase the bindi ng of
recombinan t p53 to the RGC or other unrelat ed sequences
(dat a not shown). No bin ding was obtained when p53 was
incuba ted with purified YB-1, CIEBP-{3, the Epst ein-Barr virus
transactivator Z protein , Erg1, YY1, or hea t-inactiva ted Sp1
(not shown). A minor act ivat ion of p53 bin ding was observed
with Egr-l. In terest ingly, Egr1 is a zinc finger protein with a
high homology to Sp1 in the zinc finger domain s. Erg1 has been
shown to bind not only it s specific binding sites, but also Sp 1
consensus sequences (30). Interesti ngly, another zinc finger
pr otein , WT1, has been shown to int eract with p53 (31).
Further information was obtai ned using th e LTR B sequence
(Fig. 3B ). As indicated (see Fig. lA), this probe contains th e p53
site and the flanking conse nsus Sp1 binding site. Direct binding
of Sp1, but not recombin an t p53, was detected . When both pro-
teins were assayed together , the presence of a slower mobility
band was detected . The addition of p53 also decreased the inten-
sity of the Sp1 band, suggesti ng that the upp er band may contain
both proteins. When this slow mobility complex was assayed by
UV cross-linki ng, using an LTR B probe with BrdUr d for T
substitutions at position 11 and 24 (probe LTR B-UV), both Sp1
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finding of this synergistic activation supports the in vitro data
presented in this paper indicating the cooperativity of Spl and
P53 for DNA binding. In addition, the juxtaposition of the p53
and Spl responsive elements in the HIV-l LTR suggests that this
close proximity may be necessary for the stabilization of the
interaction between these transcription factors.
It may be important to consider that the role of the p53-Spl
interaction could be extended to the regulation of the expression
of other promoters that contain Spl sites. Recent studies suggest
that phosphorylation of Spl during the Go to G1 transition may
regulate its ability to transactivate gene expression (33). Spl
binding sites, called GC boxes, are present in the promoters of
many growth-regulated genes (33). It is possible that some of
these promoters may contain Spl-p53 composite sites. This hy-
pothesis is most interesting when promoters that have been
shown to be transactivated by transforming mutant forms of p53
but do not contain known p53 binding sites are considered.
Some examples of these genes are the PCNA (14) and MDRl
genes (13). The identification of these putative p53-Spl com-
posite sites may help to understand the functions of the prolif-
erative p53 conformational state (34) and the gain-of-function
effect (26, 34) attributed to p53 mutant forms.
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FIG. 4. Transient-transfection assay showing the Spl and p53 syn-
ergy on the lllV-l LTR transcription. SL2 cells were transfected with 10
Il{5 of -121,+232 HN-1 LTR CAT or -65,+232 HIV LTR CAT reporter
plasmids, 3 Il{5 of a CMV-p53 143ala (P53), and increasing concentration of
pPAC-Sp1 (SpI). Transfection samples were adjusted using CMV and pPAC
empty vectors. Cells were incubated for 72 h and CAT activity measured as
indicated under "Experimental Procedures." CAT activity was normalized to
basal expression of the HN-1 LTR -121,+232 (5% CAT conversion). The






and p53 were identified. This experiment demonstrated that both
proteins can bind simultaneously to the DNA probe (Fig. 3C, LTR
B). These experiments suggested that the interaction with Spl
plays a role in the sequence recognition properties of p53. A
possible interpretation is that interaction with Spl allows p53 to
adopt the adequate conformation for binding to the LTR DNA
sequence. However, it is also possible that in these assays Spl is
selecting p53 protein molecules in the preparation of wild type
p53 that exhibit an appropriate conformation for interaction. The
latter hypothesis would imply growth factors or cell cycle regu-
lators induce the necessary posttranslational modifications in
p53 and Spl that allow these proteins to interact and bind Spl-
p53 composite sites.
Synergistic Transactivation between Spl and p53 in Vivo-It
has been previously shown that site-directed mutagenesis of the
LTR p53 site decreased the transactivation of the HIV-l LTR by
mutant p53 forms (6) and also that mutation of the Spl sites did
not abolish, but significantly diminished, mutant p53 transacti-
vation (19). These results indicated that multiple sites mediate
the ability ofp53 to transactivate the HIV-l LTR and that Spl is
not necessary but may be synergistic with p53 transactivation.
To characterize the functional role of the physical interaction
between Spl and p53, we sought to analyze the role of these
transcription factors in a D. melanogaster cell line, SL2, that
lacks proteins that are related to the mammalian Spl transcrip-
tion factor (32). SL2 cells were transfected with expression vec-
tors encoding p53 143ala and Spl together with the -121,+232
HIV-l LTR CAT reporter plasmid. Transfection ofp53 143ala or
Spl alone produced a minimal activation of HIV-l LTR CAT
activity. However, cotransfection of both transcription factors
resulted in a significant increase of transcription (Fig. 4). This
synergistic effect was dependent in the presence of the p53 and
Spl composite site as both factors failed to synergize when a
-65, +232 LTR deletion mutant promoter was used (Fig. 4). At
high levels of input Spl expression vector the synergy is lost.
Possibly at these levels the 5' Spl site may be saturated for
binding, thus preventing p53 from binding to its target site. The
